Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have provided informed consent.~2. Must have completed the treatment period in a parent study of EDP1815 in atopic dermatitis and complied with the parent protocol.~3. Must agree to use emollients.~4. Must continue to follow contraception criteria.~Exclusion Criteria:~1. Participants who are currently enrolled in another investigational drug study or plans to receive another investigational drug during this study.~2. Have any other conditions, which would make the participant unsuitable for inclusion or could interfere with the participant participating in or completing the study.~3. Use of phototherapy, a biologic agent, or a systemic immunosuppressive agent that could affect AD, including systemic corticosteroids, within 7 days prior to Day -1, unless used as a rescue treatment as part of the parent study protocol.~4. Use of topical atopic dermatitis therapies, including topical corticosteroids, topical calcineurin inhibitors, topical PDE-4 inhibitors, and topical JAK inhibitors, within 7 days prior to enrolling in the study, unless used as a rescue treatment as part of the EDP1815-207 protocol.~5. Has received live or live-attenuated vaccination prior to enrollment or intends to have such a vaccination during the study.~6. Hypersensitivity to P histicola or to any of the excipients.~7. Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (1.6x10^11 total cells of EDP1815, 2 capsules once daily) (Type: EXPERIMENTAL): EDP1815-207 Cohort 1 participants will receive 1.6x10\^11 total cells of EDP1815 in EDP1815-208 administered as 2 capsules once daily. (Group 1)
- Group 2 (6.4x10^11 total cells of EDP1815, 2 capsules once daily) (Type: EXPERIMENTAL): EDP1815-207 Cohort 2 participants will receive 6.4x10\^11 total cells of EDP1815 in EDP1815-208 administered as 2 capsules once daily. (Group 2)
- Group 3 (8.0x10^10 total cells of EDP1815, 1 capsule once daily) (Type: EXPERIMENTAL): EDP1815-207 Cohort 4 participants will receive 8.0x10\^10 total cells of EDP1815 in EDP1815-208 administered as 1 capsule once daily. (Group 3)

Based on this trial design, predict the completion outcome and termination type (if applicable).